Table 2.
VAERS Reporting Rates of Myocarditis (per million doses administered) after mRNA vaccine, days 0–7
| Vaccine | Age (years) | Males | Females | ||||
|---|---|---|---|---|---|---|---|
| Dose 1 | Dose 2 | Booster | Dose 1 | Dose 2 | Booster | ||
| Pfizer | 5–11 | 0.2 | 2.6 | 0 | 0.2 | 0.7 | 0 |
| Pfizer | 12–15 | 5.3 | 46.4 | 15.3 | 0.7 | 4.1 | 0 |
| Pfizer | 16–17 | 7.2 | 75.9 | 24.1 | 0 | 7.5 | 0 |
| Either | 18–24 | 4.2 | 38.9 | 9.9 | 0.6 | 4.0 | 0.6 |
| Either | 25–29 | 1.8 | 15.2 | 4.8 | 0.4 | 3.5 | 2.0 |
| Either | 30–39 | 1.9 | 7.5 | 1.8 | 0.6 | 0.9 | 0.6 |
| Either | 40–49 | 0.5 | 3.3 | 0.4 | 0.4 | 1.6 | 0.6 |
| Either | 50–64 | 0.5 | 0.7 | 0.4 | 0.6 | 0.5 | 0.1 |
| Either | ≥65 | 0.5 | 0.3 | 0.6 | 0.1 | 0.5 | 0.1 |
Either means either Pfizer or Moderna mRNA vaccine administered. Data as of 26 May 2022.
Bold numbers indicate rates that exceed calculated baseline rate in the population of 0.2–2.2 per million population.
Data presented at the Advisory Committee of the Immunization Practices Committee, June 2022.